At a glance
- Originator AstraZeneca
- Class Anthracenes; Antipsychotics
- Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Serotonin 5-HT2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psychotic disorders; Schizophrenia
Most Recent Events
- 21 Jan 2008 Discontinued - Preclinical for Schizophrenia in US Pacific Islands (PO)
- 24 May 1999 Phase-I clinical trials for Psychotic disorders in United Kingdom (PO)
- 24 May 1999 Preclinical development for Schizophrenia in US Pacific Islands (PO)